UFC-TLNP produced a reported 59.0% CAR-positive and Foxp3-positive Tfh-cell population.
Tfh cells; UFC-saRNA; in vitro · Main Figure 2B, PDF p. 4sales@dcchemicals.com
Lipid Trp-L1-T4
Formulation & Performance
Literature-reported formulation composition
| Component | Reported molar ratio | Role |
|---|---|---|
| Trp-L1-T4 | 25 | Ionizable lipid |
| Cholesterol | 20 | Sterol |
| DMG-PEG2000 | 0.5 | PEG lipid |
| DOPE | 10 | Helper phospholipid |
| Reported ratio sum | 55.5 | Original ratio retained |
Component molecular weights and calculated amounts
Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.
| Component | Molecular weight | Molar parts | Normalized mol% | Amount (µmol) | Weight (mg) |
|---|---|---|---|---|---|
| Trp-L1-T4 | 45.045 | 77.1520 | 49.3056 | ||
| Cholesterol | 36.036 | 61.7216 | 23.8647 | ||
| DMG-PEG2000 | 0.901 | 1.5430 | 3.8684 | ||
| DOPE | 18.018 | 30.8608 | 22.9614 |
Calculated total: 100.0000 mg lipid.
Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.
Literature-reported performance for the cited formulation
Literature-reported59.8%24 h after 80 ng GFP-saRNA per 50,000 cells · Selected as the lead dose with minimal cytotoxicityMain text, printed p. 592 / PDF p. 5; Supplementary Figure S1H,I
Literature-reported107.0 ± 13.4 nmPost-formulation characterization · UFC-TLNPSupplementary Table S2, SI PDF p. 12
Literature-reported0.16 ± 0.05Post-formulation characterization · UFC-TLNPSupplementary Table S2, SI PDF p. 12
Literature-reported-1.9 ± 1.5 mVPost-formulation characterization · UFC-TLNPSupplementary Table S2, SI PDF p. 12
Literature-reported85.28 ± 3.56%Post-formulation characterization · UFC-TLNPSupplementary Table S2, SI PDF p. 12
Additional reported findings
After UFC-RLNP treatment, the reported Foxp3-positive Tfh fractions were 60.6% on day 1, 56.4% on day 3, 51.9% on day 7 and 49.2% on day 14.
CXCR5-antibody-functionalized RLNP; n=3; in vitro · Main Figure 3B,C, PDF p. 6At 24 h, UFC-RLNP produced 61.3% DeltaLNGFR-positive Tfh cells versus 1.44% conventional T cells in the reported assay.
Tfh-restricted UFC-saRNA translation plus CXCR5-targeted uptake; n=3 · Main Figure 3I,JA single UFC-Tw/RLNP dose improved reported biochemical, immune and liver-histology endpoints in both prophylactic and established Ad-2D6 autoimmune-hepatitis-II mouse experiments relative to saline controls.
Female C57BL/6J mice; 5 micrograms saRNA IV on day 1 or day 28; preclinical evidence only · Main Figures 6-7 and Supplementary Figures S6-S7The authors reported no detectable red-blood-cell lysis in the tested assay, no significant Tfh cytotoxicity at tested in vitro doses, stable body weight and no treatment-associated abnormality in examined major-organ H&E sections.
Assay- and mouse-study-specific observations; not a formal toxicology program · Main Figure 2M; Supplementary Figures S1, S2G, S6A and S7GLiterature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetZheng Z, Liu Y, Wang G, et al. In vivo CAR-Tfh cell reprogramming restores tolerance in a mouse model of autoimmune hepatitis. Cell Stem Cell. 2026;33:589-604. DOI: 10.1016/j.stem.2026.02.006
Structure and lead selection: main Figure 1 and Supplementary Figure S1; base formulation: main text and Supplementary Table S1; preparation: STAR Methods; particle properties: Supplementary Table S2; targeted CAR-Tfh performance and mouse AIH-II studies: main Figures 2-7 and Supplementary Figures S2-S7.
Structure and lead selection: main Figure 1 and Supplementary Figure S1; base formulation: main text and Supplementary Table S1; preparation: STAR Methods; particle properties: Supplementary Table S2; targeted CAR-Tfh performance and mouse AIH-II studies: main Figures 2-7 and Supplementary Figures S2-S7.